U.S. clinical-stage biopharmaceutical company MacroGenics Inc. has priced its underwritten public offering of 5.5 million shares of its common stock at a public offering price of $20 per share.
The company has granted the underwriters a 30-day option to buy up to a further 825,000 shares of common stock at the public offering price.
The company expects $110 million gross proceeds from the offering before deducting underwriters’ discounts and commissions and estimated offering expenses.
MacroGenics plans to use the proceeds for general corporate purposes and working capital needs consistent with its business plan.